Seite - 7 - in Cancer Nanotheranostics - What Have We Learnd So Far?
Bild der Seite - 7 -
Text der Seite - 7 -
Condeetal. RecentAdvancesonCancerNanotheranostics
Gene expression has been targeted for silencing to avoid
mutatedprotein function to exert its role in tumorprogression.
Nanotechnology based systems shows great promise in
addressing novel genomic biomarkers that signal cancer cells,
and do it with increased sensitivity that allow early detection
of genome/genetic modifications that at the origin of cancer.
Emergent technologies have been combined with nanoscale
structures fordirecting to the siteof interestwithdecreased side
effects. The experience gathered thus far has shown that the
next step in the effective translation of nanotheranostics into
the clinics relates to the body’s response to the nanoconjugates.
What are the toxicity impacts of these devices and platforms?
Are there enoughdata for the full chronic toxicity evaluationof the applicationof these systems? Is the immune systema friend
or foe fornanotheranostics?
AUTHORCONTRIBUTIONS
All theauthorscontributedtothisEditorialpiece.All theauthors
readandrevisedthemanuscript.
ACKNOWLEDGMENTS
JCacknowledgesMarieCurieInternationalOutgoingFellowship
andFunding(FP7-PEOPLE-2013-IOF,Project626386).
REFERENCES
Bhaskar, S., Tian, F., Stoeger, T., Kreyling, W., de la Fuente, J. M., Grazú, V.,
et al. (2010).MultifunctionalNanocarriers for diagnostics, drug delivery and
targeted treatment across blood-brain barrier: perspectives on tracking and
neuroimaging.Part.FibreToxicol.7:3.doi:10.1186/1743-8977-7-3
Conde, J., Arnold, C. E., Tian, F., and Artzi, N. (2015). RNAi nanomaterials
targeting immune cells as an anti-tumor therapy: themissing link in cancer
treatment?Mater. Today. doi: 10.1016/j.mattod.2015.07.005. [Epub ahead of
print]. Available online at: http://www.sciencedirect.com/science/article/pii/
S1369702115002229
Conde, J., Doria, G., and Baptista, P. (2012). Noble metal nanoparticles
applications incancer. J.DrugDeliv. 2012:751075.doi:10.1155/2012/751075
Conde, J., Tian, F., Baptista, P. V., and de la Fuente, J. M. (2014).
“Multifunctional gold nanocarriers for cancer theranostics - from bench to bedside and back again?” inNano-Oncologicals: New Targeting AndDelivery
Approaches, ed F. Marcos Garcia (Springer International Publishing AG),
295–328.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absenceof any commercial or financial relationships that could
beconstruedasapotential conflictof interest.
Copyright © 2016Conde, Tian, de la Fuente and Baptista. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordancewith accepted academic practice.
Nouse, distributionor reproduction is permittedwhichdoes not complywith these
terms.
Frontiers inChemistry |www.frontiersin.org January2016 |Volume3 |Article71 7|
Cancer Nanotheranostics
What Have We Learnd So Far?
- Titel
- Cancer Nanotheranostics
- Untertitel
- What Have We Learnd So Far?
- Autoren
- João Conde
- Pedro Viana Baptista
- Jesús M. De La Fuente
- Furong Tian
- Herausgeber
- Frontiers in Chemistry
- Datum
- 2016
- Sprache
- englisch
- Lizenz
- CC BY 4.0
- ISBN
- 978-2-88919-776-7
- Abmessungen
- 21.0 x 27.7 cm
- Seiten
- 132
- Schlagwörter
- Nanomedicine, Nanoparticles, nanomaterials, Cancer, heranostics, Immunotherapy, bioimaging, Drug delivery, Gene Therapy, Phototherapy
- Kategorien
- Naturwissenschaften Chemie